nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCC2—esophageal cancer	0.417	0.731	CbGaD
Canagliflozin—ABCB1—esophageal cancer	0.153	0.269	CbGaD
Canagliflozin—ABCC2—Carboplatin—esophageal cancer	0.0746	0.311	CbGbCtD
Canagliflozin—ABCC2—Cisplatin—esophageal cancer	0.0638	0.266	CbGbCtD
Canagliflozin—ABCC2—Methotrexate—esophageal cancer	0.0414	0.173	CbGbCtD
Canagliflozin—ALB—Methotrexate—esophageal cancer	0.0258	0.108	CbGbCtD
Canagliflozin—UGT2B4—pericardium—esophageal cancer	0.0244	0.467	CbGeAlD
Canagliflozin—ABCB1—Cisplatin—esophageal cancer	0.0208	0.0867	CbGbCtD
Canagliflozin—ABCB1—Methotrexate—esophageal cancer	0.0135	0.0563	CbGbCtD
Canagliflozin—SLC5A1—epithelium—esophageal cancer	0.00422	0.0807	CbGeAlD
Canagliflozin—SLC5A1—bronchus—esophageal cancer	0.00416	0.0795	CbGeAlD
Canagliflozin—SLC5A1—trachea—esophageal cancer	0.00374	0.0714	CbGeAlD
Canagliflozin—Dapagliflozin—CYP2A6—esophageal cancer	0.00323	0.729	CrCbGaD
Canagliflozin—SLC5A1—digestive system—esophageal cancer	0.00321	0.0614	CbGeAlD
Canagliflozin—SLC5A1—lung—esophageal cancer	0.00268	0.0513	CbGeAlD
Canagliflozin—UGT2B4—lung—esophageal cancer	0.00247	0.0472	CbGeAlD
Canagliflozin—UGT1A9—digestive system—esophageal cancer	0.00202	0.0386	CbGeAlD
Canagliflozin—Diuresis—Cisplatin—esophageal cancer	0.00171	0.0644	CcSEcCtD
Canagliflozin—Dapagliflozin—ABCB1—esophageal cancer	0.0012	0.271	CrCbGaD
Canagliflozin—Sunburn—Methotrexate—esophageal cancer	0.000966	0.0363	CcSEcCtD
Canagliflozin—Rash macular—Capecitabine—esophageal cancer	0.000955	0.0359	CcSEcCtD
Canagliflozin—ORM1—lung—esophageal cancer	0.000889	0.017	CbGeAlD
Canagliflozin—ABCC2—digestive system—esophageal cancer	0.000875	0.0167	CbGeAlD
Canagliflozin—Serum creatinine increased—Cisplatin—esophageal cancer	0.000864	0.0324	CcSEcCtD
Canagliflozin—Prurigo—Capecitabine—esophageal cancer	0.000849	0.0319	CcSEcCtD
Canagliflozin—Infection—Carboplatin—esophageal cancer	0.000642	0.0241	CcSEcCtD
Canagliflozin—Serum creatinine increased—Capecitabine—esophageal cancer	0.000637	0.0239	CcSEcCtD
Canagliflozin—ORM1—lymph node—esophageal cancer	0.000608	0.0116	CbGeAlD
Canagliflozin—ALB—lymph node—esophageal cancer	0.000533	0.0102	CbGeAlD
Canagliflozin—Hyperkalaemia—Cisplatin—esophageal cancer	0.000522	0.0196	CcSEcCtD
Canagliflozin—Rash erythematous—Capecitabine—esophageal cancer	0.000512	0.0192	CcSEcCtD
Canagliflozin—Multiple fractures—Methotrexate—esophageal cancer	0.000502	0.0188	CcSEcCtD
Canagliflozin—Fracture—Methotrexate—esophageal cancer	0.000502	0.0188	CcSEcCtD
Canagliflozin—ABCC2—lymph node—esophageal cancer	0.0005	0.00954	CbGeAlD
Canagliflozin—CYP3A4—digestive system—esophageal cancer	0.000444	0.00849	CbGeAlD
Canagliflozin—Polyuria—Cisplatin—esophageal cancer	0.000439	0.0165	CcSEcCtD
Canagliflozin—Nocturia—Capecitabine—esophageal cancer	0.000422	0.0159	CcSEcCtD
Canagliflozin—Renal failure acute—Cisplatin—esophageal cancer	0.000418	0.0157	CcSEcCtD
Canagliflozin—ABCB1—epithelium—esophageal cancer	0.000413	0.0079	CbGeAlD
Canagliflozin—ABCB1—trachea—esophageal cancer	0.000366	0.00698	CbGeAlD
Canagliflozin—Blood creatinine increased—Cisplatin—esophageal cancer	0.000362	0.0136	CcSEcCtD
Canagliflozin—Dehydration—Cisplatin—esophageal cancer	0.000359	0.0135	CcSEcCtD
Canagliflozin—Urine output increased—Capecitabine—esophageal cancer	0.000354	0.0133	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Cisplatin—esophageal cancer	0.000352	0.0132	CcSEcCtD
Canagliflozin—Breast disorder—Cisplatin—esophageal cancer	0.000349	0.0131	CcSEcCtD
Canagliflozin—Diabetes mellitus—Capecitabine—esophageal cancer	0.000327	0.0123	CcSEcCtD
Canagliflozin—Pancreatitis—Cisplatin—esophageal cancer	0.000327	0.0123	CcSEcCtD
Canagliflozin—Photosensitivity—Capecitabine—esophageal cancer	0.000324	0.0122	CcSEcCtD
Canagliflozin—Polyuria—Capecitabine—esophageal cancer	0.000324	0.0122	CcSEcCtD
Canagliflozin—ABCB1—digestive system—esophageal cancer	0.000314	0.00601	CbGeAlD
Canagliflozin—Renal failure acute—Capecitabine—esophageal cancer	0.000308	0.0116	CcSEcCtD
Canagliflozin—Thirst—Capecitabine—esophageal cancer	0.000299	0.0112	CcSEcCtD
Canagliflozin—Cystitis noninfective—Methotrexate—esophageal cancer	0.000285	0.0107	CcSEcCtD
Canagliflozin—Cystitis—Methotrexate—esophageal cancer	0.000282	0.0106	CcSEcCtD
Canagliflozin—Vaginal infection—Methotrexate—esophageal cancer	0.000275	0.0103	CcSEcCtD
Canagliflozin—Blood creatinine increased—Capecitabine—esophageal cancer	0.000266	0.01	CcSEcCtD
Canagliflozin—Dehydration—Capecitabine—esophageal cancer	0.000265	0.00993	CcSEcCtD
Canagliflozin—Urine output increased—Methotrexate—esophageal cancer	0.000264	0.0099	CcSEcCtD
Canagliflozin—Bladder pain—Methotrexate—esophageal cancer	0.000264	0.0099	CcSEcCtD
Canagliflozin—Urinary tract disorder—Cisplatin—esophageal cancer	0.000264	0.0099	CcSEcCtD
Canagliflozin—ABCB1—lung—esophageal cancer	0.000263	0.00502	CbGeAlD
Canagliflozin—Urethral disorder—Cisplatin—esophageal cancer	0.000262	0.00982	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00026	0.00975	CcSEcCtD
Canagliflozin—Breast disorder—Capecitabine—esophageal cancer	0.000257	0.00965	CcSEcCtD
Canagliflozin—Diabetes mellitus—Methotrexate—esophageal cancer	0.000243	0.00914	CcSEcCtD
Canagliflozin—Polyuria—Methotrexate—esophageal cancer	0.000241	0.00905	CcSEcCtD
Canagliflozin—Photosensitivity—Methotrexate—esophageal cancer	0.000241	0.00905	CcSEcCtD
Canagliflozin—Erythema—Cisplatin—esophageal cancer	0.000232	0.00872	CcSEcCtD
Canagliflozin—Malnutrition—Cisplatin—esophageal cancer	0.000232	0.00872	CcSEcCtD
Canagliflozin—Renal failure acute—Methotrexate—esophageal cancer	0.000229	0.00861	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000224	0.00842	CcSEcCtD
Canagliflozin—Urinary tract infection—Capecitabine—esophageal cancer	0.000213	0.008	CcSEcCtD
Canagliflozin—Convulsion—Cisplatin—esophageal cancer	0.000201	0.00756	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000196	0.00738	CcSEcCtD
Canagliflozin—Urinary tract disorder—Capecitabine—esophageal cancer	0.000194	0.0073	CcSEcCtD
Canagliflozin—Urethral disorder—Capecitabine—esophageal cancer	0.000193	0.00724	CcSEcCtD
Canagliflozin—Breast disorder—Methotrexate—esophageal cancer	0.000191	0.00718	CcSEcCtD
Canagliflozin—Infection—Cisplatin—esophageal cancer	0.000188	0.00707	CcSEcCtD
Canagliflozin—Nervous system disorder—Cisplatin—esophageal cancer	0.000186	0.00698	CcSEcCtD
Canagliflozin—Skin disorder—Cisplatin—esophageal cancer	0.000184	0.00692	CcSEcCtD
Canagliflozin—ABCB1—lymph node—esophageal cancer	0.00018	0.00343	CbGeAlD
Canagliflozin—Pancreatitis—Methotrexate—esophageal cancer	0.000179	0.00674	CcSEcCtD
Canagliflozin—Angiopathy—Capecitabine—esophageal cancer	0.000179	0.0067	CcSEcCtD
Canagliflozin—Hypotension—Cisplatin—esophageal cancer	0.000177	0.00665	CcSEcCtD
Canagliflozin—Malnutrition—Capecitabine—esophageal cancer	0.000171	0.00643	CcSEcCtD
Canagliflozin—Erythema—Capecitabine—esophageal cancer	0.000171	0.00643	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000167	0.00627	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000164	0.00615	CcSEcCtD
Canagliflozin—Syncope—Capecitabine—esophageal cancer	0.000154	0.00577	CcSEcCtD
Canagliflozin—Loss of consciousness—Capecitabine—esophageal cancer	0.000151	0.00565	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000145	0.00544	CcSEcCtD
Canagliflozin—Urinary tract disorder—Methotrexate—esophageal cancer	0.000145	0.00543	CcSEcCtD
Canagliflozin—Urethral disorder—Methotrexate—esophageal cancer	0.000144	0.00539	CcSEcCtD
Canagliflozin—Dry mouth—Capecitabine—esophageal cancer	0.000143	0.00535	CcSEcCtD
Canagliflozin—Hypersensitivity—Cisplatin—esophageal cancer	0.00014	0.00525	CcSEcCtD
Canagliflozin—Infection—Capecitabine—esophageal cancer	0.000139	0.00521	CcSEcCtD
Canagliflozin—Shock—Capecitabine—esophageal cancer	0.000138	0.00516	CcSEcCtD
Canagliflozin—Nervous system disorder—Capecitabine—esophageal cancer	0.000137	0.00515	CcSEcCtD
Canagliflozin—Asthenia—Cisplatin—esophageal cancer	0.000136	0.00511	CcSEcCtD
Canagliflozin—Skin disorder—Capecitabine—esophageal cancer	0.000136	0.0051	CcSEcCtD
Canagliflozin—Angiopathy—Methotrexate—esophageal cancer	0.000133	0.00499	CcSEcCtD
Canagliflozin—Hypotension—Capecitabine—esophageal cancer	0.000131	0.0049	CcSEcCtD
Canagliflozin—Malnutrition—Methotrexate—esophageal cancer	0.000128	0.00479	CcSEcCtD
Canagliflozin—Erythema—Methotrexate—esophageal cancer	0.000128	0.00479	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000121	0.00453	CcSEcCtD
Canagliflozin—Fatigue—Capecitabine—esophageal cancer	0.000121	0.00453	CcSEcCtD
Canagliflozin—Rash—Cisplatin—esophageal cancer	0.00012	0.00449	CcSEcCtD
Canagliflozin—Constipation—Capecitabine—esophageal cancer	0.00012	0.00449	CcSEcCtD
Canagliflozin—Dermatitis—Cisplatin—esophageal cancer	0.000119	0.00449	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000114	0.00429	CcSEcCtD
Canagliflozin—Nausea—Cisplatin—esophageal cancer	0.000113	0.00423	CcSEcCtD
Canagliflozin—Urticaria—Capecitabine—esophageal cancer	0.000111	0.00417	CcSEcCtD
Canagliflozin—Abdominal pain—Capecitabine—esophageal cancer	0.000111	0.00415	CcSEcCtD
Canagliflozin—Convulsion—Methotrexate—esophageal cancer	0.00011	0.00415	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000108	0.00405	CcSEcCtD
Canagliflozin—Infection—Methotrexate—esophageal cancer	0.000103	0.00388	CcSEcCtD
Canagliflozin—Hypersensitivity—Capecitabine—esophageal cancer	0.000103	0.00387	CcSEcCtD
Canagliflozin—Nervous system disorder—Methotrexate—esophageal cancer	0.000102	0.00383	CcSEcCtD
Canagliflozin—Skin disorder—Methotrexate—esophageal cancer	0.000101	0.0038	CcSEcCtD
Canagliflozin—Asthenia—Capecitabine—esophageal cancer	0.0001	0.00377	CcSEcCtD
Canagliflozin—Pruritus—Capecitabine—esophageal cancer	9.89e-05	0.00371	CcSEcCtD
Canagliflozin—Hypotension—Methotrexate—esophageal cancer	9.73e-05	0.00365	CcSEcCtD
Canagliflozin—Dizziness—Capecitabine—esophageal cancer	9.25e-05	0.00347	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Methotrexate—esophageal cancer	8.99e-05	0.00337	CcSEcCtD
Canagliflozin—Fatigue—Methotrexate—esophageal cancer	8.97e-05	0.00337	CcSEcCtD
Canagliflozin—Rash—Capecitabine—esophageal cancer	8.81e-05	0.00331	CcSEcCtD
Canagliflozin—Dermatitis—Capecitabine—esophageal cancer	8.81e-05	0.00331	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Methotrexate—esophageal cancer	8.51e-05	0.0032	CcSEcCtD
Canagliflozin—Nausea—Capecitabine—esophageal cancer	8.3e-05	0.00312	CcSEcCtD
Canagliflozin—Urticaria—Methotrexate—esophageal cancer	8.27e-05	0.0031	CcSEcCtD
Canagliflozin—Abdominal pain—Methotrexate—esophageal cancer	8.23e-05	0.00309	CcSEcCtD
Canagliflozin—Hypersensitivity—Methotrexate—esophageal cancer	7.67e-05	0.00288	CcSEcCtD
Canagliflozin—Asthenia—Methotrexate—esophageal cancer	7.47e-05	0.0028	CcSEcCtD
Canagliflozin—Pruritus—Methotrexate—esophageal cancer	7.36e-05	0.00276	CcSEcCtD
Canagliflozin—Dizziness—Methotrexate—esophageal cancer	6.88e-05	0.00258	CcSEcCtD
Canagliflozin—Rash—Methotrexate—esophageal cancer	6.56e-05	0.00246	CcSEcCtD
Canagliflozin—Dermatitis—Methotrexate—esophageal cancer	6.56e-05	0.00246	CcSEcCtD
Canagliflozin—Nausea—Methotrexate—esophageal cancer	6.18e-05	0.00232	CcSEcCtD
Canagliflozin—ALB—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	5.18e-05	0.000485	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	5.17e-05	0.000485	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	5.1e-05	0.000478	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NOS2—esophageal cancer	5.02e-05	0.000471	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NOS2—esophageal cancer	5.02e-05	0.000471	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CYP19A1—esophageal cancer	4.98e-05	0.000467	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NOTCH1—esophageal cancer	4.98e-05	0.000466	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NOTCH1—esophageal cancer	4.98e-05	0.000466	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CA1—esophageal cancer	4.93e-05	0.000462	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SLC10A2—esophageal cancer	4.93e-05	0.000462	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	4.91e-05	0.00046	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	4.85e-05	0.000455	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	4.83e-05	0.000452	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	4.69e-05	0.00044	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—AQP3—esophageal cancer	4.68e-05	0.000439	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PFN1—esophageal cancer	4.67e-05	0.000438	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—PTGS2—esophageal cancer	4.63e-05	0.000434	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—HMOX1—esophageal cancer	4.55e-05	0.000426	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	4.54e-05	0.000425	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CREBBP—esophageal cancer	4.51e-05	0.000423	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CREBBP—esophageal cancer	4.51e-05	0.000423	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CA2—esophageal cancer	4.51e-05	0.000422	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	4.49e-05	0.000421	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ATP4A—esophageal cancer	4.49e-05	0.000421	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	4.4e-05	0.000413	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ABCB1—esophageal cancer	4.36e-05	0.000409	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	4.3e-05	0.000403	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	4.28e-05	0.000401	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	4.24e-05	0.000398	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ADH7—esophageal cancer	4.19e-05	0.000393	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PLCE1—esophageal cancer	4.19e-05	0.000393	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—esophageal cancer	4.15e-05	0.000389	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.14e-05	0.000388	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	4.11e-05	0.000386	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	4.1e-05	0.000385	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	4.07e-05	0.000381	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NOS3—esophageal cancer	4.04e-05	0.000379	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NOS3—esophageal cancer	4.04e-05	0.000379	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	4.02e-05	0.000377	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	3.98e-05	0.000374	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	3.93e-05	0.000369	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	3.93e-05	0.000369	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	3.91e-05	0.000367	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	3.81e-05	0.000357	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CFL1—esophageal cancer	3.78e-05	0.000355	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CREBBP—esophageal cancer	3.78e-05	0.000354	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CREBBP—esophageal cancer	3.78e-05	0.000354	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—ERBB2—esophageal cancer	3.78e-05	0.000354	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—ERBB2—esophageal cancer	3.78e-05	0.000354	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	3.77e-05	0.000353	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTGS2—esophageal cancer	3.69e-05	0.000346	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTGS2—esophageal cancer	3.69e-05	0.000346	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ADH1B—esophageal cancer	3.67e-05	0.000344	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—GNG7—esophageal cancer	3.57e-05	0.000334	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TYMP—esophageal cancer	3.51e-05	0.000329	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	3.51e-05	0.000329	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TP53—esophageal cancer	3.47e-05	0.000325	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP26A1—esophageal cancer	3.42e-05	0.00032	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	3.41e-05	0.00032	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ABCC2—esophageal cancer	3.4e-05	0.000319	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—NOS3—esophageal cancer	3.38e-05	0.000317	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—NOS3—esophageal cancer	3.38e-05	0.000317	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	3.36e-05	0.000315	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALOX15—esophageal cancer	3.33e-05	0.000312	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	3.24e-05	0.000304	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CDKN1A—esophageal cancer	3.23e-05	0.000303	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CDKN1A—esophageal cancer	3.23e-05	0.000303	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	3.2e-05	0.0003	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TPI1—esophageal cancer	3.17e-05	0.000298	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTO1—esophageal cancer	3.17e-05	0.000298	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTGS2—esophageal cancer	3.09e-05	0.00029	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTGS2—esophageal cancer	3.09e-05	0.00029	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—GNG7—esophageal cancer	3.09e-05	0.000289	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EP300—esophageal cancer	3.07e-05	0.000288	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EP300—esophageal cancer	3.07e-05	0.000288	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	3.05e-05	0.000286	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALDOB—esophageal cancer	3.04e-05	0.000285	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—BLVRB—esophageal cancer	3.03e-05	0.000284	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC52A3—esophageal cancer	3.03e-05	0.000284	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	3.01e-05	0.000282	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	2.98e-05	0.000279	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GAPDH—esophageal cancer	2.93e-05	0.000275	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CREBBP—esophageal cancer	2.92e-05	0.000273	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HSPA5—esophageal cancer	2.91e-05	0.000273	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CRABP1—esophageal cancer	2.9e-05	0.000272	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GNG7—esophageal cancer	2.76e-05	0.000259	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	2.71e-05	0.000254	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	2.71e-05	0.000254	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MYC—esophageal cancer	2.68e-05	0.000251	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MYC—esophageal cancer	2.68e-05	0.000251	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	2.68e-05	0.000251	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	2.66e-05	0.00025	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC52A3—esophageal cancer	2.66e-05	0.000249	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—BLVRB—esophageal cancer	2.66e-05	0.000249	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EGFR—esophageal cancer	2.62e-05	0.000245	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EGFR—esophageal cancer	2.62e-05	0.000245	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—NOS3—esophageal cancer	2.61e-05	0.000245	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALDH2—esophageal cancer	2.59e-05	0.000243	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CA1—esophageal cancer	2.58e-05	0.000242	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC10A2—esophageal cancer	2.58e-05	0.000242	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—EP300—esophageal cancer	2.57e-05	0.000241	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—EP300—esophageal cancer	2.57e-05	0.000241	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTT1—esophageal cancer	2.46e-05	0.000231	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP2A6—esophageal cancer	2.43e-05	0.000228	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.42e-05	0.000227	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTGS2—esophageal cancer	2.39e-05	0.000224	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CA2—esophageal cancer	2.36e-05	0.000221	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ENO1—esophageal cancer	2.31e-05	0.000216	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS1—esophageal cancer	2.31e-05	0.000216	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	2.31e-05	0.000216	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	2.3e-05	0.000215	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PSME2—esophageal cancer	2.27e-05	0.000213	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PSME1—esophageal cancer	2.27e-05	0.000213	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PIK3CA—esophageal cancer	2.27e-05	0.000213	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PIK3CA—esophageal cancer	2.27e-05	0.000213	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC10A2—esophageal cancer	2.26e-05	0.000212	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CA1—esophageal cancer	2.26e-05	0.000212	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.25e-05	0.000211	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	2.23e-05	0.000209	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PLCE1—esophageal cancer	2.19e-05	0.000206	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ADH7—esophageal cancer	2.19e-05	0.000206	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	2.18e-05	0.000204	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.17e-05	0.000203	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ABL1—esophageal cancer	2.15e-05	0.000202	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CA2—esophageal cancer	2.07e-05	0.000194	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—EP300—esophageal cancer	1.99e-05	0.000186	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.98e-05	0.000186	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	1.97e-05	0.000185	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP1B1—esophageal cancer	1.96e-05	0.000184	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ADH1B—esophageal cancer	1.92e-05	0.00018	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PLCE1—esophageal cancer	1.92e-05	0.00018	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ADH7—esophageal cancer	1.92e-05	0.00018	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.91e-05	0.000179	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CA—esophageal cancer	1.9e-05	0.000178	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CA—esophageal cancer	1.9e-05	0.000178	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.88e-05	0.000176	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP19A1—esophageal cancer	1.84e-05	0.000173	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TYMP—esophageal cancer	1.84e-05	0.000172	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	1.81e-05	0.00017	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ABCB1—esophageal cancer	1.81e-05	0.000169	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP26A1—esophageal cancer	1.79e-05	0.000168	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALOX15—esophageal cancer	1.74e-05	0.000163	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ADH1B—esophageal cancer	1.69e-05	0.000158	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—HMOX1—esophageal cancer	1.68e-05	0.000158	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTO1—esophageal cancer	1.66e-05	0.000156	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TPI1—esophageal cancer	1.66e-05	0.000156	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.65e-05	0.000155	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.65e-05	0.000155	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC52A3—esophageal cancer	1.64e-05	0.000154	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—BLVRB—esophageal cancer	1.64e-05	0.000154	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ABCB1—esophageal cancer	1.62e-05	0.000151	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TYMP—esophageal cancer	1.61e-05	0.000151	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALDOB—esophageal cancer	1.59e-05	0.000149	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.58e-05	0.000148	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.57e-05	0.000147	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS2—esophageal cancer	1.55e-05	0.000146	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.55e-05	0.000145	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GAPDH—esophageal cancer	1.53e-05	0.000144	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALOX15—esophageal cancer	1.53e-05	0.000143	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CRABP1—esophageal cancer	1.52e-05	0.000143	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CA—esophageal cancer	1.47e-05	0.000138	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TPI1—esophageal cancer	1.46e-05	0.000137	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTO1—esophageal cancer	1.46e-05	0.000137	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GNG7—esophageal cancer	1.45e-05	0.000136	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALDOB—esophageal cancer	1.4e-05	0.000131	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CREBBP—esophageal cancer	1.39e-05	0.000131	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CA1—esophageal cancer	1.39e-05	0.000131	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.39e-05	0.000131	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	1.36e-05	0.000128	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALDH2—esophageal cancer	1.36e-05	0.000127	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GAPDH—esophageal cancer	1.34e-05	0.000126	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.34e-05	0.000126	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CRABP1—esophageal cancer	1.33e-05	0.000125	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.3e-05	0.000122	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTT1—esophageal cancer	1.29e-05	0.000121	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP2A6—esophageal cancer	1.27e-05	0.000119	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CA2—esophageal cancer	1.27e-05	0.000119	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.27e-05	0.000119	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GNG7—esophageal cancer	1.27e-05	0.000119	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS3—esophageal cancer	1.25e-05	0.000117	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.22e-05	0.000114	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ENO1—esophageal cancer	1.21e-05	0.000113	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS1—esophageal cancer	1.21e-05	0.000113	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.21e-05	0.000113	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PSME1—esophageal cancer	1.19e-05	0.000112	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PSME2—esophageal cancer	1.19e-05	0.000112	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALDH2—esophageal cancer	1.19e-05	0.000111	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.18e-05	0.000111	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ADH7—esophageal cancer	1.18e-05	0.000111	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTT1—esophageal cancer	1.13e-05	0.000106	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.12e-05	0.000105	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CREBBP—esophageal cancer	1.08e-05	0.000101	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ENO1—esophageal cancer	1.06e-05	9.92e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS1—esophageal cancer	1.06e-05	9.92e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.06e-05	9.91e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PSME2—esophageal cancer	1.04e-05	9.78e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PSME1—esophageal cancer	1.04e-05	9.78e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.04e-05	9.74e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.04e-05	9.73e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP1B1—esophageal cancer	1.03e-05	9.63e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TYMP—esophageal cancer	9.92e-06	9.3e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NOS3—esophageal cancer	9.67e-06	9.06e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP19A1—esophageal cancer	9.66e-06	9.05e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP26A1—esophageal cancer	9.65e-06	9.05e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—EP300—esophageal cancer	9.49e-06	8.9e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALOX15—esophageal cancer	9.41e-06	8.82e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP1B1—esophageal cancer	9e-06	8.43e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTO1—esophageal cancer	8.97e-06	8.41e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TPI1—esophageal cancer	8.97e-06	8.41e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—esophageal cancer	8.84e-06	8.29e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HMOX1—esophageal cancer	8.81e-06	8.26e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.64e-06	8.1e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALDOB—esophageal cancer	8.6e-06	8.06e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP19A1—esophageal cancer	8.46e-06	7.93e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCB1—esophageal cancer	8.46e-06	7.93e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GAPDH—esophageal cancer	8.28e-06	7.76e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CRABP1—esophageal cancer	8.21e-06	7.69e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GNG7—esophageal cancer	7.81e-06	7.32e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HMOX1—esophageal cancer	7.72e-06	7.24e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—EP300—esophageal cancer	7.35e-06	6.89e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALDH2—esophageal cancer	7.31e-06	6.86e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CA—esophageal cancer	7.02e-06	6.58e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTT1—esophageal cancer	6.96e-06	6.52e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP2A6—esophageal cancer	6.88e-06	6.45e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—esophageal cancer	6.79e-06	6.37e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ENO1—esophageal cancer	6.52e-06	6.11e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS1—esophageal cancer	6.52e-06	6.11e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PSME1—esophageal cancer	6.42e-06	6.02e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PSME2—esophageal cancer	6.42e-06	6.02e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.39e-06	5.99e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CREBBP—esophageal cancer	5.65e-06	5.3e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP1B1—esophageal cancer	5.54e-06	5.2e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CA—esophageal cancer	5.44e-06	5.1e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP19A1—esophageal cancer	5.21e-06	4.89e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NOS3—esophageal cancer	5.06e-06	4.74e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CREBBP—esophageal cancer	4.95e-06	4.64e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HMOX1—esophageal cancer	4.76e-06	4.46e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—esophageal cancer	4.63e-06	4.34e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCB1—esophageal cancer	4.57e-06	4.28e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NOS3—esophageal cancer	4.43e-06	4.16e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—esophageal cancer	4.06e-06	3.8e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—EP300—esophageal cancer	3.85e-06	3.61e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—EP300—esophageal cancer	3.37e-06	3.16e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.05e-06	2.86e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CA—esophageal cancer	2.85e-06	2.67e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NOS3—esophageal cancer	2.73e-06	2.56e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.5e-06	2.34e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.49e-06	2.34e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—EP300—esophageal cancer	2.08e-06	1.95e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.54e-06	1.44e-05	CbGpPWpGaD
